Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Thursday, Zacks reports.
Separately, Jefferies Financial Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Three analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat, the stock currently has a consensus rating of “Strong Buy”.
Get Our Latest Stock Report on SGIOY
Shionogi & Co., Ltd. Unsponsored ADR Stock Performance
SGIOY stock traded up $0.09 during trading on Thursday, reaching $9.22. 163,940 shares of the stock were exchanged, compared to its average volume of 95,038. Shionogi & Co., Ltd. Unsponsored ADR has a twelve month low of $7.83 and a twelve month high of $12.00. The company has a current ratio of 1.14, a quick ratio of 1.00 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $15.69 billion, a P/E ratio of 9.22, a price-to-earnings-growth ratio of 3.27 and a beta of 0.08. The stock has a 50 day simple moving average of $9.07 and a 200-day simple moving average of $9.27.
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.13% and a net margin of 46.67%. The firm had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $970.69 million. As a group, sell-side analysts anticipate that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current year.
Shionogi & Co., Ltd. Unsponsored ADR Company Profile
Shionogi & Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Osaka. Founded in 1878, the company discovers, develops, manufactures and markets prescription medicines, with a focus on infectious diseases, central nervous system disorders and other areas of unmet medical need.
Shionogi’s portfolio includes Xofluza (baloxavir marboxil), an antiviral treatment for influenza, and F. (fostemsavir), an HIV treatment marketed in certain regions. The company also develops medicines for conditions including pain, psychiatric disorders and other diseases, while pursuing research in areas such as antimicrobial resistance and novel anti-infective therapies.
Shionogi primarily serves the Japanese market and has expanded its international presence through subsidiaries, licensing arrangements and commercial partnerships in North America, Europe and other regions.
See Also
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
